‘Excellent’ Outcomes After Complete Response in Lymph Node-Positive Breast Cancer
Patients with early lymph node-positive breast cancer and pathologic complete response (pCR) after neoadjuvant therapy had similar long-term recurrence rates and survival regardless of the type of adjuvant therapy they received, a Dutch registry study showed. After a median follow-up of 6 years, regional recurrence rates ranged from 3.0-4.1% whether they had conservative axillary surgery […]
Noninvasive Therapy Shows Efficacy in Non-Muscle-Invasive Bladder Cancer
WASHINGTON — An investigational non-surgical treatment led to a “robust” complete response rate in patients with recurrent, low-grade non-muscle-invasive bladder cancer, the phase III ENVISION study showed. Patients treated with the UGN-102 (mitomycin) intravesical solution achieved a complete response rate of 79.2% (95% CI 73.5-84.1) at 3 months without having to undergo transurethral resection of […]
Complete PCI Better for Older MI Patients Too
AMSTERDAM — Complete revascularization improved outcomes over culprit-lesion-only stenting in older acute myocardial infarction (MI) patients, the FIRE trial affirmed. Among a population ages 75 and older, the composite risk of death, MI, stroke, or any revascularization came out a relative 27% less common when addressing all the stenosed vessels during the same hospitalization (15.7% […]
‘Fantastic,’ ‘Terrific’ Results With Oncolytic Virus Combo for Bladder Cancer
CHICAGO — An oncolytic virus therapy combined with pembrolizumab (Keytruda) produced complete responses (CRs) in 85% of patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), a small phase II trial showed. The results showed CRs in 29 of 34 patients with detectable carcinoma in situ (CIS) treated with cretostimogene grenadenorepvec (CG0070) and the PD-1 […]
Immediate Complete Revascularization Non-Inferior to Staged Procedure
NEW ORLEANS – Immediate complete revascularization was non-inferior to staged complete revascularization in patients who presented with acute coronary syndrome (ACS) and multivessel disease, according to BIOVASC trial findings. In the prospective, open-label study, the composite primary outcome occurred in 7.6% of 764 patients in the immediate complete revascularization group and in 9.4% of 761 […]
Intermittent fasting may reverse type 2 diabetes, according to study: Study finds people with diabetes who fast intermittently may no longer need medication
After an intermittent fasting diet intervention, patients achieved complete diabetes remission, defined as an HbA1c (average blood sugar) level of less than 6.5% at least one year after stopping diabetes medication, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Intermittent fasting diets have become popular in recent […]
High Rates of pCR With Novel Neoadjuvant Combination for Breast Cancer
SAN ANTONIO — A novel neoadjuvant regimen for HER2-negative breast cancer doubled the pathologic complete response (pCR) rate as compared with standard chemotherapy, a small phase II study showed. Across various breast cancer receptor signatures, pCR rates ranged from 36% to 53% with the combination of paclitaxel, the PD-1 inhibitor cemiplimab (Libtayo), and the investigational […]
Study Suggests Potential to Skip Surgery for Selected Breast Cancer Patients
Women who chose not to have surgery after a pathologic complete response (pCR) to neoadjuvant therapy for early HER2-positive or triple-negative breast cancer (TNBC) had no recurrences during the first 2 years of follow-up, a small prospective study showed. Overall, 31 of 50 (62%) women had no evidence of residual disease by image-guided vacuum-assisted core […]
Prenatal Steroids May Improve Outcomes in Extremely Preterm Infants
A complete course of antenatal steroids was associated with higher survival in extremely preterm infants, a cohort study showed. Among infants born at 22 weeks to less than 24 weeks, 53.9% who had full exposure to antenatal steroids at gestational age 21 to 22 weeks survived to discharge, compared with 37.5% who had partial steroid […]
Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition
CHICAGO — Single-agent dostarlimab (Jemperli) led to complete responses in 100% of a small group of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, allowing them to avoid surgery, chemotherapy, and radiation, at least for the time being. All 14 patients followed for at least 6 months had clinical complete responses with no evidence […]